In addition, independent of PD‐L1 expression or TMB status, PAPPA2 mutation displayed a strong association with better clinical outcomes in patients with NSCLC and SKCM after receiving ICIs therapy. Here, PAPPA2 is linked to non-small cell lung carcinoma.